Medications as social phenomena

Health

Volumn 5, Issue 4, 2001, Pages 441-469

  Cohen, David ^a,e   McCubbin, Michael ^b   Collin, Johanne ^c   Pérodeau, Guilhème ^d  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b UNIVERSITY OF REGINA   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DU QUÉBEC EN OUTAOUAIS   (Canada)

^e Florida International University ^*  (United States)

Author keywords

Constructivism; Critical analysis; General system theory; Pharmaceuticals; Psychotropic medications; Social change

Indexed keywords

EID: 0001492293     PISSN: 13634593     EISSN: None     Source Type: Journal    
DOI: 10.1177/136345930100500403     Document Type: Article

References (142)

1. Abraham, J. (1995). Science, politics and the pharmaceutical industry: Controversy and bias in drug regulation. London: UCL.
2. Adams, K.M. and Bieliauskas, L.A. (1994). On perhaps becoming what you had previously despised: Psychologists as prescribers of medication. Journal of Clinical Psychology in Medical Settings, 1, 189-97.
3. Agency for Health Care Policy and Research (AHCPR). (1999). Treatment of depression: Newer pharmacotherapies. Summary, evidence report/technology assessment 7. Rockville, MD: AHCPR. Available at: http://www.ahcpr.gov/clinic/deprsumm.htm [accessed 13 July 2001].
4. Antonuccio, D., Danton, W.G., DeNelsky, G.Y., Greenberg, R.G. and Gordon, J.S. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68, 3-14.
5. Baberg, H.T., Nelesen, R.A. and Dimsdale, J.E. (1996). Amphetamine use: Return of an old scourge in a consultation psychiatry setting. American Journal of Psychiatry, 153, 789-93.
6. Barden, L.S., Dowell, S.F., Schwartz, B. and Lackey, C. (1998). Current attitudes regarding use of antimicrobial agents: Results from physician's and parents' focus group discussions. Clinical Pediatrics, 37, 665-71.
7. Baum, C., Kennedy, D.L., Knapp, D.E., Juergens, J.P. and Faich, G.A. (1988). Prescription drug use in 1984 and changes over time. Medical Care, 26, 105-14.
8. Bernstein, A. and Lennard, H.L. (1973). The American way of drugging: Drugs, doctors and junkies. Society, May/June, 14-25.
9. Bond, P. (1999). Globalization, pharmaceutical pricing, and South African health policy: Managing confrontation with US firms and politicians. International Journal of Health Services, 29, 765-92.
10. Bowler, T.D. (1981). General systems thinking: Its scope and applicability. New York: North Holland.
11. Braddock, C.H., III, Fihn, S.D., Levinson, W., Jonson, A.R. and Pearlman, R.A. (1997). How doctors and patients discuss routine clinical decisions: Informed decision making in the outpatient setting. Journal of General Internal Medicine, 12, 339-45.
12. Breggin, P.R. (1997). Brain-disabling treatments in psychiatry: Drugs, electroshock, and the role of the FDA. New York: Springer.
13. Breggin, P.R. and Cohen, D. (1999). Your drug may be your problem: How and why to stop taking psychiatric medications. Cambridge, MA: Perseus.
14. Bush, P.J. (1977). Psychosocial aspects of medicine use. In A.I. Wertheimer and PJ. Bush (Eds.), Perspectives on medicines in society. Hamilton, IL: Drug Intelligence.
15. Bush, P.J. and Osterweis, M. (1978). Pathways to medicine use. Journal of Health and Social Behavior, 19, 179-89.
16. Buske, L. (2000). Drug costs surpass spending on physicians. Canadian Medical Association Journal, 162, 405-6.
17. Butler, C.C., Rollnick, S., Pill, R., Maggs-Rapport, F. and Stott, N. (1998). Understanding the culture of prescribing: Qualitative study of general practitioners' and patients' perceptions of antibiotics for sore throats. BMJ, 317, 637-42.
18. Calhoun, C.J. (1995). Critical social theory: Culture, history, and the challenge of difference. Oxford: Blackwell.
19. Chinburapa, V., Larson, L.N. and Brucks, M. (1993). Physician prescribing decisions: The effects of situational involvement and task complexity on information acquisition and decision making. Social Science & Medicine, 36, 1473-82.
20. Christensen-Szalanski, J.J.J. and Bushyhead, J.B. (1988). Physicians' use of probabilistic information in a real clinical setting. In J. Dowie and A. Elstein (Eds.), Professional judgment: A reader in clinical decision making. Cambridge: Cambridge University Press.
21. Coambs, R.B., Jensen, P., Hao Her, M., Ferguson, B.F., Larry, J.L., Wong, J.S.W, et al. (1995). Review of the scientific literature on the prevalence, consequences, and health costs of compliance and inappropriate use of prescription medication in Canada. Toronto: University of Toronto Press.
22. Cobert, B. and Silvey, J. (1999). The Internet and drug safety: What are the implications for pharmacovigilance? Drug Safety, 20, 95-107.
23. Cohen, D. (1996). Les 'nouveaux' médicaments de l'esprit: Marche avant vers le passé? (The 'new' mind drugs: Forward step into the past?) Sociologie et sociétés, 28, 17-34.
24. Cohen, D. (1997a). A critique of the use of neuroleptic drugs in psychiatry. In S. Fisher and R.P. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test. New York: Wiley.
25. Cohen, D. (1997b). Psychiatrogenics: Introducing chlorpromazine in psychiatry. Review of Existential Psychology and Psychiatry, 23, 206-33.
26. Cohen, D. and Bisson, J. (1997). Médication neuroleptique et risque de dyskinésie tardive: Une enquête auprès de psychiatres et d'omnipraticiens du Québec (Neuroleptic medication and the risk of tardive dyskinesia: A survey of psychiatrists and general practitioners in Québec). Santé mentale au Québec, 22, 263-82.
27. Cohen, D. and Karsenty, S. (1998). Représentations sociales des effets secondaires des anxiolytiques: Une étude comparative Québec-France (Social representations of the side effects of anxiolytics: A comparative Québec-France study). Montreal & Paris: GRASP & Hôpital La Salpêtrière.
28. Cohen, D. and McCubbin, M. (1990). The political economy of tardive dyskinesia: Asymmetries in power and responsibility. Journal of Mind and Behavior, 11, 465-88.
29. Collin, J. (1999). Rationalité et irrationalité à l'origine des mésusages des médicaments (Rationality and irrationality at the origin of medication misuse). Actualité et Dossiers en Santé Publique, 27, 55-8.
30. Collin, J., Damestoy, N. and Lalande, R. (1999). La construction d'une rationalité: Les médecins face à la prescription de psychotropes aux personnes âgées (Constructing a rationality: Physicians and the prescription of psychotropics to the elderly). Sciences Sociales et Santé, 17, 31-52.
31. Conrad, P. (1994). The meaning of medications: Another look at compliance. In P. Conrad and R. Kern (Eds.), The sociology of health and illness: Critical perspectives. New York: St Martin's.
32. Damestoy, N., Collin, J. and Lalande, R. (1999). Physicians' perception of psychotropic medication prescriptions for elderly patients: Another perspective. Canadian Medical Association Journal, 161, 143-5.
33. Davidson, W., Molloy, W. and Bédard, M. (1995). Physician characteristics and prescribing for elderly people in New Brunswick: Relation to patient outcomes. Canadian Medical Association Journal, 152, 1227-34.
34. Davis, P. (1996). Contested ground: Public purpose and private interest in the regulation of prescription drugs. New York: Oxford University Press.
35. DeGiacomo, P., Silvestri, A., Pierri, G., Lefons, E. and Corfiati, L. (1986). Research on effects of psychodrugs on human interaction. A theoretical/experimental approach. Acta Psychiatrica Scandinavica, 74, 417-24.
36. DeGrandpre, R. (1999). Ritalin nation: Rapid-fire culture and the transformation of human consciousness. New York: Norton.
37. Diller, L.H. (1996). The run on Ritalin: Attention-deficit disorder and stimulant treatment in the 1990s. Hastings Center Report, March/April.
38. Diller, L.H. (2000). Kids on drugs: A behavioral pediatrician questions the wisdom of medicating our children. Salon Health and Body, 9 March. Available at: http:/wwv.salon.com/health/feature/2000/03/09/kid_drugs/[accessed 13 July 2001].
39. Donovan, J.L. and Blake, D.R. (1992). Patient non-compliance: Deviance or reasoned decision-making? Social Science & Medicine, 34, 507-13.
40. Ehrenberg, A. (1995). L'individu incertain (The uncertain individual). Paris: Calmann-Lévy.
41. Eichenwald, K. and Kolata, G. (1999). Drug trials hide conflicts for doctors. New York Times, 16 May, 1.
42. Estroff, S.E. (1985). Making it crazy: An ethnography of psychiatric clients in an American community. Berkeley, CA: University of California Press.
43. Fineman, H. (1991). The social construction of noncompliance. Sociology of Health and Illness, 13, 354-74.
44. Fisher, S. and Greenberg, R.P. (1993). How sound is the double-blind design for evaluating psychotropic drugs? Journal of Nervous and Mental Disease, 181, 345-50.
45. Fisher, S. and Greenberg, R.P., Eds. (1997). From placebo to panacea: Putting psychiatric drugs to the test. New York: Wiley.
46. Fried, S. (1998). Bitter pills: Inside the hazardous world of legal drugs. New York: Bantam.
47. Gabe, J., Ed. (1991). Understanding tranquilliser use: Contributions from the social sciences. London: Tavistock/Routledge.
48. Gabe, J. and Lipshitz-Phillips, S. (1984). Tranquillisers as social control? Sociological Review, 36, 320-52.
49. Gergen, K.J. (1985). Social constructionist inquiry: Context and implications. In K.J. Gergen and K.E. Davis (Eds.), The social construction of the person. New York: Springer-Verlag.
50. Gerrity, M.S., Earp, J.A.L., DeVellis, R.F. and Light, D.W. (1992). Uncertainty and professional work: Perceptions of physicians in clinical practice. American Journal of Sociology, 97, 1022-51.
51. Giddens, A. (1990). The consequences of modernity. Stanford, CA: Stanford University Press.
52. Goldsmith, J. (2000). How will the Internet change our health system? Health Affairs, March/April. Available at: http://www.projhope.org/HA/bonus/190112.htm [accessed 13 July 2001].
53. Grinspoon, L. and Hedblom, P. (1975). The speed culture: Amphetamine use and abuse in America. Cambridge, MA: Harvard University Press.
54. Gutierrez, P.M. and Silk, K.R. (1998). Prescription privileges for psychologists: A review of the psychological literature. Professional Psychology-Research and Practice, 29, 213-22.
55. Haafkens, J. (1997). Rituals of silence. Long-term tranquilizer use by women in the Netherlands: A social case study. Amsterdam: University of the Netherlands Press.
56. Hailey, D. (2000). Scientific harassment by pharmaceutical companies: Time to stop. Canadian Medical Association Journal, 162, 212-13.
57. Healy, D. (1999). The three faces of the antidepressants: A critical commentary on the clinical-economic context of diagnosis. Journal of Nervous and Mental Disease, 187, 174-80.
58. Henney, J.E., Shuren, J.E., Nightingale, S.L. and McGinnis, T.J. (1999). Internet purchases of prescription drugs: Buyer beware. Annals of Internal Medicine, 131, 861-2.
59. Huxley, A. (1954). The doors of perception. London: Chatto & Windus.
60. Illich, I. (1976). Medical nemesis: The expropriation of health. New York: Pantheon.
61. IMS Health. (2000a). IMS Health reports 10 percent growth in global retail drug sales for 12 month period to February. Available at http://www.imshealth.com/html/news_arc/04_20_2000_351.htm (accessed 5 September 2000).
62. IMS Health. (2000b). IMS Health reports US pharmaceutical promotional spending reached record $13.9 billion in 1999. Available at: http://www.imshealth.corn/html/news_arc/04_20_2000_352.htm (accessed 5 September 2000).
63. International Narcotics Control Board. (2000). Report of the International Narcotics Control Board for 1999. New York: United Nations.
64. Jack, D.B. (1997). One hundred years of aspirin. Lancet, 350, 437-9.
65. Jacobs, D.J. (1995). Psychiatric drugging: 40 years of pseudo-science, self-interest, and indifference to harm. Journal of Mind and Behavior, 16, 421-70.
66. Jacobs, D.J. and Cohen, D. (1999). What is really known about psychological alterations produced by psychiatric drugs? International Journal of Risk and Safety in Medicine, 12, 37-47.
67. Karp, D.A. (1996). Speaking of sadness: Depression, disconnection, and the meanings of illness. New York: Oxford University Press.
68. Keen, E. (1998). Drugs, therapy, and professional power. Westport, CT: Praeger.
69. Kelly, M.P. and Field, D. (1997). Body image and sociology: A reply to Simon Williams. Sociology of Health and Illness, 19, 359-66.
70. Kleinman, D.L. and Cohen, L.J. (1991). The decontextualization of mental illness: The portrayal of work in psychiatric drug advertisements. Social Science & Medicine, 32, 867-74.
71. Kogan, M.D., Pappas, G., Yu, S.M. and Kotelchuk, M. (1994). Over-the-counter medication use among US preschool-age children. JAMA, 272, 1025-30.
72. Kopferschmitt, J., Meyer, P., Jaeger, A., Mantz, J.M. and Roos, M. (1992). Troubles du sommeil et consommation de médicaments psychotropes chez l'enfant de six ans (Sleep disorders and consumption of psychotropic medications with respect to the six-year-old child). Revue d'épidémiologique et de Santé Publique, 40, 467-71.
73. Laing, R. (1999). The world health and drug situation. International Journal of Risk and Safety in Medicine, 12, 51-7.
74. Lazarou, J., Pomeranz, B.H. and Corey, P. (1998). Incidence of adverse drug reactions in hospitalized patients. JAMA, 279, 1200-5.
75. Lehrman, N.S. and Sharav, V.H. (1997). Ethical problems in psychiatric research. Journal of Mental Health Administration, 24, 227-50.
76. Lenglet, R. and Topuz, B. (1998). Des lobbies contre la santé (Lobbies against health). Paris: Syros.
77. Lexchin, J. (1993). Interactions between physicians and the pharmaceutical industry. Canadian Medical Association Journal, 149, 1401-7.
78. Lexchin, J. (1999). Direct-to-consumer advertising: Impact on patient expectations regarding disease management. Disease Management and Health Outcomes, 5, 273-83.
79. McCubbin, M. (1998). Global anarchy: Market failure, the prisoner's dilemma, and sovereignty over health and social policy. Paper presented at Xth International Conference, International Association of Health Policy, Perugia, Italy. Available at: http://www.mailbase.ac.uk/lists/radical-psychology-network/2000-02/0177.html [accessed 13 July 2001].
80. McCubbin, M. and Cohen, D. (1996). Extremely unbalanced: Interest divergence and power disparities between clients and psychiatry. International Journal of Law and Psychiatry, 19, 1-25.
81. McCubbin, M. and Cohen, D. (1999a). A systemic and value-based approach to strategic reform of the mental health system. Health Care Analysis, 7, 57-77.
82. McCubbin, M. and Cohen, D. (1999b). Empirical, ethical and political perspectives on the use of methylphenidate. Ethical Human Sciences and Services, 1, 81-101.
83. McGrath, J.M. (1999). Physicians' perspectives on communicating prescription drug information. Qualitative Health Research, 9, 731-45.
84. Makoul, G., Arntson, P. and Schofield, T. (1995). Health promotion in primary care: Physician-patient communication and decision making about prescription medications. Social Science & Medicine, 41, 1241-54.
85. Meador, C.K. (1998). Polypharmacy: Old bad habits. Journal of the American Board of Family Practice, 11, 166-7.
86. Medawar, C. (1992). Power and dependence. London: Social Audit.
87. Medawar, C. (1997). The antidepressant web. International Journal of Risk and Safety in Medicine, 10, 75-126.
88. Medawar, C. (1999). Direct-to-consumer advertising. Available at: http://www.socialaudit.org.uk/5111-002.htm/#Dear [accessed 13 July 2001].
89. Mishara, B. (1997). L'écologie familiale et la consommation de médicaments chez les personnes âgées (Family ecology and the consumption of medications by elderly persons). Santé mentale au Québec, 22, 200-15.
90. Montagne, M. (1988). The metaphorical nature of drugs and drug-taking. Social Science & Medicine, 26, 417-24.
91. Montagne, M. (1996). The Pharmakon phenomenon: Cultural conceptions of drugs and drug use. In P. Davis (Ed.), Contested ground: Public concern and private interest in the regulation of pharmaceuticals. New York: Oxford University Press.
92. Montagne, M. (1997). De l'activité pharmacologique à l'usage des drogues: La construction des connaissances sur les psychotropes (From pharmacological activity to the use of drugs: The construction of knowledge about psychotropics). Santé mentale au Québec, 22, 149-63.
93. Moore, T.J., Psaty, B.M. and Furberg, C.D. (1998). Time to act on drug safety. JAMA, 279, 1571-3.
94. Morant, N. (1998). The social representations of mental ill-health in communities of mental health practitioners in the UK and France. Information sur les Sciences Sociales, 37, 663-85.
95. Nichter, M. and Vuckovic, N. (1994). Agenda for an anthropology of pharmaceutical practice. Social Science & Medicine, 11, 1509-25.
96. O'Harrow, R., Jr (2000). Grass roots seeded by drugmaker. The Washington Post, 12 September, A1.
97. Ohayon, M.M., Caulet, M., Priest, R.G. and Guilleminault, C. (1998). Psychotropic medication consumption patterns in the UK general population. Journal of Clinical Epidemiology, 51, 273-83.
98. Olivieri, S., Cantopher, T. and Edwards, J.G. (1986). Two hundred years of anxiolytic drug dependence. Neuropharmacology, 25, 669-70.
99. Olson, J.A. (1994). Vitamins: The tortuous path from needs to fantasies. Journal of Nutrition, 124, Supplement, S1771-S1776.
100. Payer, L. (1990). Medicine and culture: Notions of health and sickness in Britain, the US, France, and West Germany. London: Gollancz.
101. Pérodeau, G. and Galbaud du Fort, G. (2000). Psychotropic drug use and the relation between social support, life events and mental health in the elderly. Journal of Applied Gerontology, 19, 23-41.
102. Pérodeau, G., King, S. and Ostoj, M. (1992) Stress and psychotropic drug use among the elderly: An exploratory model. Canadian Journal on Aging, 11, 347-69.
103. Pérodeau, G., Jomphe-Hill, A., Hay-Paquin, L. and Amyot, E. (1996). Les psychotropes et le vieillissement normal: Une perspective psychosociale et socioéconomique (Psychotropics and normal aging: A psychosocial and socioeconomic perspective). Canadian Journal on Aging, 15, 559-82.
104. Pharmaceutical Research and Manufacturers of America. (2000). New medicines in development for mental illness. Available at: http://www.phrma.org/searchcures/newmeds/mentalill/surv2000/[accessed 13 July 2001].
105. Pignarre, P. (1995). Les deux médecines: Médicaments, psychotropes et suggestion thérapeutique (The two medicines: Medications, psychotropics, and therapeutic suggestion). Paris: La Découverte.
106. Pincus, H.A., Tanielian, T.L., Marcus, S.C., Olfson, M., Zarin, D.A., Thompson, J. et al. (1998). Prescribing trends in psychotropic medications: Primary care, psychiatry, and other medical specialties. JAMA, 279, 526-31.
107. Prather, J. (1991). Decoding advertising: The role of communication studies in explaining the popularity of tranquillisers. In J. Gabe (Ed.), Understanding tranquilliser use. London: Tavistock/Routledge.
108. Prilleltensky, I. (1996). Human, moral, and political values for an emancipatory psychology. Humanist Psychologist, 24, 307-24.
109. Raje, N. and Anderson, K. (1999). Thalidomide: A revival story. New England Journal of Medicine, 341, 1606-9.
110. Ray, L. (1991). The political economy of long-term minor tranquilliser use. In J. Gabe (Ed.), Understanding tranquilliser use. London: Tavistock/Routledge.
111. Rogers, A., Day, J.C., Williams, B., Randall, F., Wood, P., Healy, D. and Bentall, R.P. (1998). The meaning and management of neuroleptic medication: A study of patients with a diagnosis of schizophrenia. Social Science and Medicine, 47, 1313-23.
112. Rome, H.P. (1986). Personal reflections: The Rx as talisman. Psychiatric Annals, 16, 566.
113. Roter, D.L. and Frankel, R. (1992). Quantitative and qualitative approaches to the evaluation of the medical dialogue. Social Science & Medicine, 34, 1097-103.
114. Roughead, E.E., Harvey, K.J. and Gilbert, A.L. (1998). Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Australian and New Zealand Journal of Medicine, 28, 306-10.
115. Sacristan, J.A. (1994). Drug utilisation studies as tools in health economics. Pharmacoeconomics, 5, 299-312.
116. Sands, W.L. (1965). The tranquilizer tablet. Talisman for the 1960s. Psychiatric Quarterly, 39, 722-6.
117. Sclar, D.A., Robison, L.M., Skaer, T.L. and Galin, R.S. (1998). What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters. International Journal of Psychiatry in Medicine, 28, 407-19.
118. Searight, H.R. (1996). Perceptions of attention deficit/hyperactivity disorder and its treatment among children and adolescents. Journal of Medical Humanities, 17, 51-61.
119. Shapiro, A.K. and Shapiro, E. (1997). The powerful placebo: From ancient priest to modern physician. Baltimore, MD: Johns Hopkins University Press.
120. Sice, J., Levine, H.D., Levin, J. and Haertzen, C.A. (1975). Effects of personal interactions and settings on subjective drug responses in small groups. Psychopharmacologia, 43, 181-6.
121. Silverstein, K. (1999). Prozac.org. Mother Jones, December, 18-19.
122. Spiegel, D. (Ed.). (1999). Efficacy and cost-effectiveness of psychotherapy. Washington, DC: American Psychiatric Press.
123. Stein, H.F. (1990). In what systems do alcohol/chemical addictions make sense? Clinical ideologies and practices as cultural metaphors. Social Science & Medicine, 30, 987-1000.
124. Sutherland, J.W. (1973). A general systems philosophy for the social and behavioral sciences. New York: Braziller.
125. Szasz, T.S. (1974). Ceremonial chemistry: The ritual persecution of drugs, addicts, and pushers. New York: Anchor.
126. Taylor, C. (1989). Sources of the self: The making of the modern identity. Cambridge, MA: Harvard University Press.
127. Thornley, B. and Adams, C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ, 317, 1181-4.
128. Trostle, J.A. (1988). Medical compliance as an ideology. Social Science & Medicine, 27, 1299-308.
129. Van der Geest, S., Whyte, S.R. and Hardon, A. (1996). The anthropology of pharmaceuticals: A biographical approach. Annual Review of Anthropology, 25, 153-78.
130. Velody, I. and Williams, R., Eds. (1998). The politics of constructivism. London: Academy of Hebrew Language.
131. Volkow, N.D., Ding, Y., Fowler, J.S., Wang, G., Logan, J., Gatley, J.S., Dewey, S., Ashby, C., Lieberman, J., Hitzemann, R. and Wolf, A.P. (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General Psychiatry, 52, 456-63.
132. Vuckovic, N. and Nichter, M. (1997). Changing patterns of pharmaceutical practice in the United States. Social Science & Medicine, 44, 1285-302.
133. Walker, M.J. (1994). Dirty medicine: Science, big business and the assault on natural health care, revised edn. London: Slingshot.
134. Wazana, A. (2000). Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA, 283, 373-80.
135. Wertheimer, A.I. and Smith, M.C., Eds. (1974). Pharmacy practice: Social and behavioral aspects. London: University Park.
136. Wilkes, M.S., Bell, R.A. and Kravitz, R.L. (2000). Direct-to-consumer prescription drug advertising: Trends, impact, and implications. Health Affairs, 19(2), 110-28.
137. Williams, S.J. and Calnan, M. (1996). The 'limits' of medicalization?: Modern medicine and the lay populace in late modernity. Social Science & Medicine, 42, 1609-20.
138. Witte, B. (1999). Judge cites hyperactivity drug in homicide acquittal. Associated Press dispatch, 25 October. Available at: www.abcnews.go.com/sections/living/DailyNews/adderall991025.html [accessed 13 July 2001].
139. Wolff, N. (1989). Professional uncertainty and physician medical decision-making in a multiple treatment framework. Social Science & Medicine, 28, 99-107.
140. Wysowski, D.K. and Baum, C. (1991). Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Archives of Internal Medicine, 151, 1779-83.
141. Zarifian, E. (1996). Le prix du bien-être. Psychotropes et societé (The price of well-being. Psychotropics and society). Paris: Odile Jacob.
142. Zito, J.M., Safer, D.J., dosReis, S., Gardner, J.F., Boles, M. and Lynch, F. (2000). Trends in the prescribing of psychotropic medications to preschoolers. JAMA, 283, 1025-30.